| Entry |
|
|---|
| Name |
Emtricitabine (JAN/USAN/INN);
Emtriva (TN)
|
|---|
| Product |
|
|---|
| Formula |
C8H10FN3O3S
|
|---|
| Exact mass |
247.0427
|
|---|
| Mol weight |
247.2467
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antiviral
DG01890 Nucleoside reverse transcriptase inhibitor (NRTI)
DG01440 Arabinofuranosyl type antiviral
DG01656 HIV reverse transcriptase inhibitor
Transporter substrate
DG02860 SLC22A8 (OAT3) substrate
|
|---|
| Remark |
| Therapeutic category: | 6250 |
|
|---|
| Efficacy |
Antiviral, Reverse transcriptase inhibitor |
|---|
| Disease |
|
|---|
| Target |
RNA-directed DNA polymerase |
|---|
| Metabolism |
Transporter: SLC22A8 [HSA: 9376]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF09 Emtricitabine
D01199 Emtricitabine (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)v
Emtricitabine
D01199 Emtricitabine (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D01199 Emtricitabine (JAN/USAN/INN)
Antiinfectives [br08350.html]
Antivirals
D01199
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D01199
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01199
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01199
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01199
 |
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 16
1 N4y N 25.0103 -17.6390
2 C1y C 23.6350 -18.1111
3 C1y C 21.3970 -18.1111
4 C1b C 20.1381 -17.4117
5 O1a O 18.9492 -18.1111
6 S2x S 21.8166 -19.4399
7 O2x O 22.5160 -17.2718
8 C1x C 23.2154 -19.4399
9 C8x C 25.0206 -16.2402
10 C8y C 26.2146 -15.5496
11 C8y C 27.4684 -16.2582
12 N5x N 27.4581 -17.6570
13 C8y C 26.2641 -18.3476
14 N1a N 28.6624 -15.5676
15 X F 26.1549 -14.1509
16 O5x O 26.2538 -19.7463
BOND 17
1 8 6 1
2 4 5 1
3 2 1 1 #Down
4 3 4 1 #Down
5 6 3 1
6 1 9 1
7 9 10 2
8 10 11 1
9 11 12 2
10 12 13 1
11 13 1 1
12 3 7 1
13 11 14 1
14 7 2 1
15 10 15 1
16 2 8 1
17 13 16 2
|
|---|
